does medicare cover any glp 1 medication GLP-1 Weight Loss Drugs? Medicare Just Changed Course on

By binding to GLP-1 receptors throughout the body, semaglutide triggers multiple physiological responses that affect both glucose metabolism and appetite regulation

Novo Nordisks semaglutide, marketed as Wegovy for people with obesity and Ozempic for those with Type 2 diabetes, has been on the FDA Drug Shortages list since August 2022

Research published in major endocrinology journals has shown that patients prescribed GLP-1 receptor agonists do not experience higher rates of cancer diagnosis compared to those receiving other diabetes medicines

Written by Samantha Farpour, L26 Introduction One-in-eight, or about 13%, of American adults have used a GLP-1 receptor agonist drug (GLP-1 RA), with higher percentages of younger adults using the drugs primarily for weight loss as compared to adults ages sixty-five years and older

Because of the limitations of this type of study, the research cant prove that hormone therapy directly caused the additional weight loss but it supports the idea that estrogen may influence how some women respond to GLP-1s